This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Assertio, Bausch say Glumetza doesn't have monopoly over diabetes treatment

( February 17, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Assertio Therapeutics and Bausch Health told a US judge that purchasers of Glumetza cannot claim they had market power over diabetes treatments, given the number of interchangeable products that use Metformin Hydrochloride as an ingredient. “Plaintiffs’ motion simply ignores the evidence that Glumetza has fiercely competed with other metformin-based treatments, including Fortamet, Glucophage, and Glucophage XR, and their generic equivalents, since coming to market,” they said in opposing the judgment.  See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections